[VIRTUAL] Nursing Experience With the Use of Ibrutinib for the First-Line Treatment of Patients With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

[VIRTUAL] SAFETY AND MANAGEMENT OF ADVERSE EVENTS WITH CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM CARTITUDE-1

[VIRTUAL] Nursing Experience With Patients Receiving Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom s Macroglobulinemia: Five Years of Follow-Up From the Phase 3 iNNOVATETM Study

[VIRTUAL] Long-term Efficacy of Neratinib in HER2-Positive Early-Stage Breast Cancer: Overall Survival and Central Nervous System Outcomes from the Phase 3 ExteNET Trial

[VIRTUAL] Isatuximab Updates for Nurses: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients (IKEMA)

[VIRTUAL] Darolutamide significantly improves overall survival with a tolerable safety profile in men with non-metastatic castration-resistant prostate cancer

[VIRTUAL] What Can Patients With Prostate Cancer Expect From Treatment With Apalutamide? Health-Related Quality of Life in Patients With Nonmetastatic Castration-Resistant Prostate Cancer in the Phase 3 SPARTAN Study

[VIRTUAL] Real-World Prognostic Biomarker Testing and Nursing Experience from the Prospective Observational Registry informCLL for Patients Receiving Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

[VIRTUAL] Treatment Experience and Pyrexia Management in a Patient With Stage III Melanoma Receiving Adjuvant BRAF/MEK-Targeted Therapy

[VIRTUAL] Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice

[VIRTUAL] The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial

[VIRTUAL] Treatment with Enzalutamide in Men with Non-metastatic Prostate Cancer from the PROSPER Trial